165 related articles for article (PubMed ID: 32427851)
1. Somatic SF3B1 hotspot mutation in prolactinomas.
Li C; Xie W; Rosenblum JS; Zhou J; Guo J; Miao Y; Shen Y; Wang H; Gong L; Li M; Zhao S; Cheng S; Zhu H; Jiang T; Ling S; Wang F; Zhang H; Zhang M; Qu Y; Zhang Q; Li G; Wang J; Ma J; Zhuang Z; Zhang Y
Nat Commun; 2020 May; 11(1):2506. PubMed ID: 32427851
[TBL] [Abstract][Full Text] [Related]
2. The SF3B1
Guo J; Li C; Fang Q; Liu Y; Wang D; Chen Y; Xie W; Zhang Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):26. PubMed ID: 35039052
[TBL] [Abstract][Full Text] [Related]
3. Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients.
Hou C; Xiao L; Ren X; Tang F; Guo B; Zeng W; Liang C; Yan N
Ophthalmic Res; 2020; 63(3):358-368. PubMed ID: 31614358
[TBL] [Abstract][Full Text] [Related]
4. Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis.
Liu B; Liu Z; Chen S; Ki M; Erickson C; Reis-Filho JS; Durham BH; Chang Q; de Stanchina E; Sun Y; Rabadan R; Abdel-Wahab O; Chandarlapaty S
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33031100
[TBL] [Abstract][Full Text] [Related]
5. A mutation of the β-domain in POU1F1 causes pituitary deficiency due to dominant PIT-1β expression.
Suzuki S; Matsuo K; Ito Y; Kobayashi A; Kokumai T; Furuya A; Ueda O; Mukai T; Yano K; Fujieda K; Okuno A; Tanahashi Y; Azuma H
Eur J Endocrinol; 2021 May; 185(1):1-12. PubMed ID: 33886498
[TBL] [Abstract][Full Text] [Related]
6. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel somatic mutation of POU6F2 by whole-genome sequencing in prolactinoma.
Miao Y; Li C; Guo J; Wang H; Gong L; Xie W; Zhang Y
Mol Genet Genomic Med; 2019 Dec; 7(12):e1022. PubMed ID: 31692290
[TBL] [Abstract][Full Text] [Related]
8. Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1.
Zhang J; Ali AM; Lieu YK; Liu Z; Gao J; Rabadan R; Raza A; Mukherjee S; Manley JL
Mol Cell; 2019 Oct; 76(1):82-95.e7. PubMed ID: 31474574
[TBL] [Abstract][Full Text] [Related]
9. Induction of GH, PRL, and TSH beta mRNA by transfection of Pit-1 in a human pituitary adenoma-derived cell line.
Miyai S; Yoshimura S; Iwasaki Y; Takekoshi S; Lloyd RV; Osamura RY
Cell Tissue Res; 2005 Nov; 322(2):269-77. PubMed ID: 16133148
[TBL] [Abstract][Full Text] [Related]
10. U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing.
Choi N; Liu Y; Oh J; Ha J; Zheng X; Shen H
Cells; 2020 Dec; 9(12):. PubMed ID: 33317029
[TBL] [Abstract][Full Text] [Related]
11. [Melatonin inhibits the proliferation of pituitary prolactin-secreting tumor by suppressing the enhancer elements mutation of PRL gene in the rat].
Gao L; Yang QH; Xu RK
Sheng Li Xue Bao; 2005 Jun; 57(3):319-27. PubMed ID: 15968426
[TBL] [Abstract][Full Text] [Related]
12. PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance.
de Castro Moreira AR; Trarbach E; Bueno CBF; Monteiro ALS; Grande IPP; Padula M; Maciel GAR; Glezer A
J Clin Endocrinol Metab; 2023 Jun; 108(7):e450-e457. PubMed ID: 36638053
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the aberrant splicing of MAP3K7 induced by cancer-associated SF3B1 mutation.
Li Z; Zhao B; Shi Y; Liang Y; Qian R; Wan Y
J Biochem; 2021 Sep; 170(1):69-77. PubMed ID: 33751071
[TBL] [Abstract][Full Text] [Related]
14. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
[TBL] [Abstract][Full Text] [Related]
15. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
16. Pituitary prolactin-secreting tumor formation: recent developments.
Xu RK; Wu XM; Di AK; Xu JN; Pang CS; Pang SF
Biol Signals Recept; 2000; 9(1):1-20. PubMed ID: 10686432
[TBL] [Abstract][Full Text] [Related]
17. Suppression of prolactin expression by cabergoline requires prolactin regulatory element-binding protein (PREB) in GH3 cells.
Zhang W; Murao K; Imachi H; Iwama H; Chen K; Fei Z; Zhang X; Ishida T; Tamiya T
Horm Metab Res; 2010 Jul; 42(8):557-61. PubMed ID: 20411477
[TBL] [Abstract][Full Text] [Related]
18. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
Hintzsche JD; Gorden NT; Amato CM; Kim J; Wuensch KE; Robinson SE; Applegate AJ; Couts KL; Medina TM; Wells KR; Wisell JA; McCarter MD; Box NF; Shellman YG; Gonzalez RC; Lewis KD; Tentler JJ; Tan AC; Robinson WA
Melanoma Res; 2017 Jun; 27(3):189-199. PubMed ID: 28296713
[TBL] [Abstract][Full Text] [Related]
19. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
[TBL] [Abstract][Full Text] [Related]
20. Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases.
Yavuzyigitoglu S; Koopmans AE; Verdijk RM; Vaarwater J; Eussen B; van Bodegom A; Paridaens D; Kiliç E; de Klein A;
Ophthalmology; 2016 May; 123(5):1118-28. PubMed ID: 26923342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
